...
search icon
apto-img

Aptose Biosciences Inc, Common Stock

APTO

NAQ

$0.207

+$0

(0%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$12.46M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
264.85K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
1.36
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$0.13 L
$2.22 H
$0.207

About Aptose Biosciences Inc, Common Stock

Aptose Biosciences Inc., a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology primarily in the United States. The company's clinical-stage oral kinase inhibitors include tuspetinib (HM43239), a once-daily oral kinase inhibitor that has completed Phase 1/2 clinical trial targeting a select group of kinases operative in myeloid malignancies, such as acute myeloid leukemia and the higher risk myelodysplastic syndromes; and luxeptinib (CG-806), a potent oral small molecule, which is in Phase 1 a/b clinical trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia, small lymphocytic lymphoma, and certain non-Hodgkin's lymphomas, as well as relapsed or refractory acute myeloid leukemia. It has license agreements with CrystalGenomics Invites Co. Ltd. to research, develop, and commercialize luxeptinib; with National Cancer Institute for the clinical development of tuspetinib; and Hanmi Pharmaceutical Co Ltd. to research, develop, and commercialize tuspetinib. The company was formerly known as Lorus Therapeutics Inc. and changed its name to Aptose Biosciences Inc. in August 2014. Aptose Biosciences Inc. was incorporated in 1986 and is headquartered in Toronto, Canada. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameAPTOSectorS&P500
1-Week Return-5.91%0.67%2.09%
1-Month Return9.41%0.9%-2.28%
3-Month Return-43.75%-8.29%1.84%
6-Month Return-69.2%-6.2%5.01%
1-Year Return-90.72%0.64%24.87%
3-Year Return-98.92%6.34%29.85%
5-Year Return-99.76%34.53%79.28%
10-Year Return-99.76%99.76%194.94%

Financials

Dec '19Dec '20Dec '21Dec '22Dec '235YR TREND
Total Revenue-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Cost of Revenue627.25K646.43K616.53K507.08K474.55K[{"date":"2019-12-31","value":97.03,"profit":true},{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":95.37,"profit":true},{"date":"2022-12-31","value":78.44,"profit":true},{"date":"2023-12-31","value":73.41,"profit":true}]
Gross Profit(627.25K)(646.43K)(616.53K)(507.08K)(474.55K)[{"date":"2019-12-31","value":-62725100,"profit":false},{"date":"2020-12-31","value":-64643500,"profit":false},{"date":"2021-12-31","value":-61652700,"profit":false},{"date":"2022-12-31","value":-50707900,"profit":false},{"date":"2023-12-31","value":-47454500,"profit":false}]
Gross Margin(Infinity%)(Infinity%)(Infinity%)(Infinity%)(Infinity%)[{"date":"2019-12-31","value":null,"profit":false},{"date":"2020-12-31","value":null,"profit":false},{"date":"2021-12-31","value":null,"profit":false},{"date":"2022-12-31","value":null,"profit":false},{"date":"2023-12-31","value":null,"profit":false}]
Operating Expenses26.86M55.77M65.45M42.60M52.36M[{"date":"2019-12-31","value":41.04,"profit":true},{"date":"2020-12-31","value":85.21,"profit":true},{"date":"2021-12-31","value":100,"profit":true},{"date":"2022-12-31","value":65.09,"profit":true},{"date":"2023-12-31","value":80,"profit":true}]
Operating Income(26.86M)(55.78M)(65.45M)(42.59M)(52.36M)[{"date":"2019-12-31","value":-2686300000,"profit":false},{"date":"2020-12-31","value":-5577600000,"profit":false},{"date":"2021-12-31","value":-6544600000,"profit":false},{"date":"2022-12-31","value":-4259300000,"profit":false},{"date":"2023-12-31","value":-5235600000,"profit":false}]
Total Non-Operating Income/Expense1.16M1.05M187.00K1.57M2.53M[{"date":"2019-12-31","value":45.85,"profit":true},{"date":"2020-12-31","value":41.58,"profit":true},{"date":"2021-12-31","value":7.39,"profit":true},{"date":"2022-12-31","value":61.94,"profit":true},{"date":"2023-12-31","value":100,"profit":true}]
Pre-Tax Income(26.28M)(55.24M)(65.35M)(41.82M)(51.21M)[{"date":"2019-12-31","value":-2627700000,"profit":false},{"date":"2020-12-31","value":-5523800000,"profit":false},{"date":"2021-12-31","value":-6535400000,"profit":false},{"date":"2022-12-31","value":-4182300000,"profit":false},{"date":"2023-12-31","value":-5120700000,"profit":false}]
Income Taxes(580.00K)(530.00K)(93.00K)(770.00K)(3.00)[{"date":"2019-12-31","value":-58000000,"profit":false},{"date":"2020-12-31","value":-53000000,"profit":false},{"date":"2021-12-31","value":-9300000,"profit":false},{"date":"2022-12-31","value":-77000000,"profit":false},{"date":"2023-12-31","value":-300,"profit":false}]
Income After Taxes(25.70M)(54.71M)(65.26M)(41.05M)(51.21M)[{"date":"2019-12-31","value":-2569700000,"profit":false},{"date":"2020-12-31","value":-5470800000,"profit":false},{"date":"2021-12-31","value":-6526100000,"profit":false},{"date":"2022-12-31","value":-4105300000,"profit":false},{"date":"2023-12-31","value":-5120699700,"profit":false}]
Income From Continuous Operations(26.28M)(55.24M)(65.35M)(41.82M)(49.25M)[{"date":"2019-12-31","value":-2627700000,"profit":false},{"date":"2020-12-31","value":-5523800000,"profit":false},{"date":"2021-12-31","value":-6535400000,"profit":false},{"date":"2022-12-31","value":-4182300000,"profit":false},{"date":"2023-12-31","value":-4925200000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2019-12-31","value":"-","profit":true},{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true}]
Net Income(25.70M)(54.71M)(65.26M)(41.05M)(51.21M)[{"date":"2019-12-31","value":-2569700000,"profit":false},{"date":"2020-12-31","value":-5470800000,"profit":false},{"date":"2021-12-31","value":-6526100000,"profit":false},{"date":"2022-12-31","value":-4105300000,"profit":false},{"date":"2023-12-31","value":-5120700000,"profit":false}]
EPS (Diluted)(0.52)(0.67)(0.73)(0.45)(5.62)[{"date":"2019-12-31","value":-52,"profit":false},{"date":"2020-12-31","value":-67,"profit":false},{"date":"2021-12-31","value":-73,"profit":false},{"date":"2022-12-31","value":-45,"profit":false},{"date":"2023-12-31","value":-562,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

APTO
Cash Ratio 0.82
Current Ratio 1.05

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

APTO
ROA (LTM) -136.29%
ROE (LTM) -694.13%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

APTO
Debt Ratio Lower is generally better. Negative is bad. 1.84
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -0.84

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

APTO
Trailing PE NM
Forward PE NM
P/S (TTM) 0.00
P/B 67.84
Price/FCF NM
EV/R 0.00
EV/Ebitda 0.05
PEG NM

FAQs

What is Aptose Biosciences Inc share price today?

Aptose Biosciences Inc (APTO) share price today is $0.207

Can Indians buy Aptose Biosciences Inc shares?

Yes, Indians can buy shares of Aptose Biosciences Inc (APTO) on Vested. To buy Aptose Biosciences Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in APTO stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of Aptose Biosciences Inc be purchased?

Yes, you can purchase fractional shares of Aptose Biosciences Inc (APTO) via the Vested app. You can start investing in Aptose Biosciences Inc (APTO) with a minimum investment of $1.

How to invest in Aptose Biosciences Inc shares from India?

You can invest in shares of Aptose Biosciences Inc (APTO) via Vested in three simple steps:

  • Click on Sign Up or Invest in APTO stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in Aptose Biosciences Inc shares
What is Aptose Biosciences Inc 52-week high and low stock price?

The 52-week high price of Aptose Biosciences Inc (APTO) is $2.22. The 52-week low price of Aptose Biosciences Inc (APTO) is $0.13.

What is Aptose Biosciences Inc price-to-earnings (P/E) ratio?

The price-to-earnings (P/E) ratio of Aptose Biosciences Inc (APTO) is

What is Aptose Biosciences Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of Aptose Biosciences Inc (APTO) is 67.84

What is Aptose Biosciences Inc dividend yield?

The dividend yield of Aptose Biosciences Inc (APTO) is 0.00%

What is the Market Cap of Aptose Biosciences Inc?

The market capitalization of Aptose Biosciences Inc (APTO) is $12.46M

What is Aptose Biosciences Inc’s stock symbol?

The stock symbol (or ticker) of Aptose Biosciences Inc is APTO

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top